Eugen F. Mesaros

Evolution of a Total Synthesis of (−)-Kendomycin Exploiting a Petasis−Ferrier Rearrangement/Ring-Closing Olefin Metathesis Strategy

Amos B. Smith, Eugen F. Mesaros, Emmanuel A. Meyer · Journal of the American Chemical Society · 2006 · 94 citations

Medicinal Chemistry, Biosynthesis, Bioorganic Chemistry +14

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)

Gregory R. Ott, Mangeng Cheng, Keith S. Learn et al. · Journal of Medicinal Chemistry · 2016 · 88 citations · Full text

Tumor Biology, Clinical Candidate Cep-37440, Lymphoid Neoplasia +14

Total Synthesis of (−)-Kendomycin Exploiting a Petasis−Ferrier Rearrangement/Ring-Closing Olefin Metathesis Synthetic Strategy

Amos B. Smith, Eugen F. Mesaros, Emmanuel A. Meyer · Journal of the American Chemical Society · 2005 · 74 citations

A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-<i>a</i>]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779

Benjamin J. Dugan, Diane E. Gingrich, Eugen F. Mesaros et al. · Journal of Medicinal Chemistry · 2012 · 62 citations · Full text

2,7-Disubstituted-pyrrolo[2,1-<i>f</i>][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity

Gregory R. Ott, Gregory J. Wells, Tho V. Thieu et al. · Journal of Medicinal Chemistry · 2011 · 42 citations · Full text

Tumor Biology, Medicinal Chemistry, Diversity Oriented Synthesis +15